Drug Profile


Alternative Names: 742457; GSK 742457; RVT-101; SB-742457

Latest Information Update: 21 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Developer Axovant Sciences; GlaxoSmithKline
  • Class
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease
  • Phase II Dementia; Lewy body disease

Most Recent Events

  • 19 Jul 2017 Pharmacodynamic results from a preclinical study in Alzheimer's disease released by Axovant Sciences
  • 13 Jun 2017 Axovant Sciences completed enrolment in the phase IIb HEADWAY-DLB trial for Lewy body disease in USA (PO, Tablet) before June 2017
  • 09 Jan 2017 Axovant Sciences completes enrolment in the Phase-III MINDSET trial in Alzheimer's disease (Adjunctive treatment) in USA, Taiwan, Hungary, Slovakia, Singapore, Serbia, Poland, South Korea, Italy, France, Czech Republic, Croatia, Canada, Australia, Australia, Argentina (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top